Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 Success [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 SuccessDec. 21, 2022 10:57 AM ETMadrigal Pharmaceuticals, Inc. (MDGL)Edward Zhang50 Follower sSummaryklickit24/iStock via Getty ImagesIntroductionWhen Madrigal Pharmaceuticals (NASDAQ:phase two trial resultsfully vindicated in a larger and longer phase three trial, the stock trades at only ~$250 a share. Questions lingered following the positive results in 2018 regarding how Resmetirom would perform in a larger and longer clinical trial designed with statistical power to detect efficacy. Those questions have been answered. And the path forward for NDA submission is clear. But that does not explain the valuation discrepancy.In my view, the price action of Monday's trading session misses the sheer commercial opportunity at hand for Madrigal. Desensitized by consistent disappointments in the NASH sphere, it may take time for the market to digest how truly impactful this deve
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 72% of the company [Yahoo! Finance]Yahoo! Finance
- Can This High-Flying Stock 10x in 10 Years? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- 11 Oversold MidCap Stocks To Buy Now [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 4/24/24 - Beat
VKTX
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/2/24 - Form 4
- VKTX's page on the SEC website